Personalised Immunotherapy Platform (PIP)
PIP is a tool developed by MIA to ensure advanced melanoma patients receive effective treatment the first time, based on their own genetics and tumour biology.
PIP is a tool developed by MIA to ensure advanced melanoma patients receive effective treatment the first time, based on their own genetics and tumour biology.
Melanoma March events across the country to fund ground-breaking clinical trial into psychological stresses experienced by advanced melanoma patients.
The ABC-X clinical trial seeks to determine if the addition of radiotherapy, to combination immunotherapy, results in improved outcomes for patients with melanoma brain metastases.
In a world-first, an early phase trial of an mRNA personalised cancer vaccine has shown promising results for preventing melanoma recurrence in patients with resected high-risk melanoma (stage III and IV).
It was another big month of inspiring community fundraisers! From car shows, marathons and headshaves, to the selling of marmalade, monitors and swimming pools, we thank you all those who supported us over the past month.
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
Watch videos of presentations from the Melanoma Community Forum held in Hobart on 3rd November 2022.
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.
Read more about our 'Run from the Sun' 2022 campaign, including presentations to secondary schools and colleges, and fundraising rides.
From coastal walks and bridge runs, to beard shaves and pig races, we shine the spotlight on our wonderful community fundraisers.